References
Use of three-dimensional acellular collagen matrix in deep or tunnelling diabetic foot ulcers: a retrospective case series
Abstract
Objective:
While most xenograft wound matrices are flat sheets not designed for deep or tunnelling wounds, three-dimensional acellular collagen matrices (3D-ACM) can fill deep wound beds and enable full wound wall apposition. This case series examines the use of 3D-ACM in treating diabetic foot ulcers (DFUs) that are deep, tunnelling, undermining, or irregularly shaped. We report outcomes of cases where 3D-ACM was applied to deep or tunnelling DFUs present for at least four weeks.
Method:
In this retrospective case series, 3D-ACM was applied, healing was monitored and measurements were collected. Additional 3D-ACM was applied as needed.
Results:
In total, 11 patients with 13 wounds were treated. Improved wound appearance and reduced size were observed at most follow-ups. Mean initial wound depth was 1.6cm, and several wounds showed significant depth reductions shortly after therapy initiation. In total, 62% of wounds (8/13) reached 50% closure by four weeks. Additionally, 54% (7/13) were fully closed by 12 weeks. The remaining 46% (6/13) took between 12–22.3 weeks to heal. Overall mean therapy time was 13.1 weeks (range: 2.0–22.3 weeks). Deeper wounds generally took longer to close.
Conclusion:
The findings of this case series showed that 3D-ACM could offer a protective microenvironment for wound management for deep or tunnelling DFUs. While some took >12 weeks to close, this may be attributable to large initial depths and volumes, rather than a failure to respond to the treatment modality. Other wounds that require a conforming 3D matrix, enabling full wound wall apposition, may benefit from 3D-ACM. Further investigations would be beneficial to understand the capabilities of thistreatment modality.
An estimated 38.4 million people in the US live with diabetes, constituting 11.6% of the population.1 Globally, as of 2021, the number of adults with diabetes has been estimated at 537 million.2 Among the diabetic population, the prevalence of diabetic foot ulcers (DFUs) ranges from 4–10%, with the lifetime risk of developing a DFU ranging from 15–25%.3,4 Moreover, according to a 2017 study, the annual incidence of DFUs worldwide ranged from 9.1–26.1 million.5
DFUs are a major source of morbidity for patients with diabetes and can impose considerable physical, psychological and financial burdens.6,7 DFUs are often associated with peripheral neuropathy and peripheral arterial disease of the lower limb. Reduced blood flow and lack of sensation in the lower limb mean that many DFUs worsen or become infected without the patient noticing. Roughly 50–60% of DFUs develop infections; of those, 20% result in lower extremity amputations.8 It is estimated that 85% of all amputations involving patients with diabetes are preceded by a hard-to-heal (chronic) DFU that has deteriorated to a severe infection or gangrene.9
Register now to continue reading
Thank you for visiting Wound Central and reading some of our peer-reviewed resources for wound care professionals. To read more, please register today. You’ll enjoy the following great benefits:
What's included
-
Access to clinical or professional articles
-
New content and clinical updates each month